● Recruiting

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Condition: Anaplastic Thyroid Cancer · Thyroid Cancer · BRAF Mutation-Related Tumors · Sponsor: UNC Lineberger Comprehensive Cancer Center

PhasePhase 1

Planned participants12

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).

This description comes directly from the study's public registry record.

Talk to the study team

Rose Hall · 1-(919) 966-0808 · rose_hall@med.unc.edu

Lori Stravers · 1-(919) 966-4432 · lori_stravers@med.unc.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Dana Farber/Harvard Cancer Center	Boston, Massachusetts, United States	Not Yet Recruiting
University of North Carolina at Chapel Hill	Chapel Hill, North Carolina, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06902376